Canagliflozin (Invokana), a Novel Oral Agent For Type-2 Diabetes
|
|
- Hector Flowers
- 8 years ago
- Views:
Transcription
1 DrUG FOrECAST Canagliflozin (Invokana), a Novel Oral Agent For Type-2 Diabetes Sheila Sarnoski-Brocavich, BS, MS, PharmD, BCACP, CGP; and Olga Hilas, PharmD, MPH, BCPS, CGP INTRODUCTION The prevalence of diabetes in the U.S. has more than tripled, from 5.6 million to 20.9 million over the last three decades, with type-2 diabetes accounting for 90% to 95% of the diagnosed cases. 1,2 It is projected that one in three American adults will have diabetes in 2050 if this trend continues. 3 Type-2 diabetes mellitus is a progressive disease resulting from an insulin secretory defect characterized by insulin resistance and some degree of insulin deficiency. 4 The prevalence of the disease is increased in obese patients, minority populations, and the elderly. 2,5 Chronic long-term hyperglycemia associated with diabetes is the cause of serious complications, including blindness, kidney failure, amputations, and death. 2 The economic burden associated with complications of diabetes in the U.S. was $245 billion in Oral hypoglycemia agents and insulin are standard therapeutic approaches, along with lifestyle modifications, to manage type-2 diabetes and to prevent Dr. Sarnoski-Brocavich is Assistant Clinical Professor in Clinical Pharmacy Practice at St. John s University College of Pharmacy and Health Sciences, in Queens, New York, and Ambulatory Care Affiliate Pharmacy Faculty at Queens Hospital Center in Jamaica, New York. Dr. Hilas is Associate Clinical Professor in Clinical Pharmacy Practice at St. John s University College of Pharmacy and Health Sciences in Queens. She is also a Clinical Pharmacy Manager of Internal Medicine/ Geriatrics at New York Presbyterian Hospital, Weill Cornell Medical Center, in New York, New York. Drug Forecast is a regular column coordinated by Alan Caspi, PhD, PharmD, MBA, President of Caspi & Associates in New York, New York. Disclosure: The authors report that they have no commercial or financial relationships in regard to this article. complications. 7,8 Despite current available therapies, about 50% of patients in the U.S. are not achieving their goals for glycosylated hemoglobin (HbA 1c ), blood pressure, and low-density lipoprotein-cholesterol (HDL-C) levels, as recommended by the American Diabetes Association (ADA), and 81.2% are reported to be deficient in meeting all three goals. 8 Metformin (Glucophage, Bristol-Myers Squibb) is considered the initial standard of care unless it is contraindicated. 7 Insulin with or without additional agents can be added to treat newly diagnosed type-2 diabetes in patients with elevated glucose or elevated HbA 1c levels. 7 A second oral agent such as a glucagon-like peptide (GLP) receptor agonist, a dipeptidyl peptidase IV (DPP-4) inhibitor, a peroxisome proliferator-activated receptor (PPAR) agonist, or insulin may be required if non-insulin monotherapy has been ineffective in achieving HbA 1c goals within 3 to 6 months. 7 Recent recommendations from the ADA and the European Association for the Study of Diabetes (EASD), along with the American Association of Clinical Endocrinologists (AACE), advise a patient-centered approach to management. 9,10 Preferred medications are those that carry a low risk of hypoglycemia, minimize the risk of weight gain, are easy to administer, are cost-effective, and are safe to use. 10 In March 2013, the FDA approved canagliflozin (Invokana, Janssen) as an adjunct to diet and exercise for adults with type-2 diabetes mellitus. This is the first oral agent in a novel class of diabetes drugs known as sodium glucose co-transporter-2 (SGLT-2) inhibitors. 11 Current research has focused on the role of the kidney in glucose homeostasis and has identified the role of SGLT-2 in mediating the reabsorption of filtered glucose in the proximal tubule. 11,12 The inhibition of SGLT-2 provides a novel mechanism to lower elevated plasma glucose levels in diabetic patients. 12,13 PHARMACOLOGY AND MECHANISM OF ACTION SGLT-2 is a high-capacity, low-affinity transporter located in the brush border of the membrane of the early segment of the proximal tubule. Canagliflozin is an SGLT-2 inhibitor that increases glucose excretion in the urine by reducing reabsorption of filtered glucose and lowering the renal glucose threshold. The structural formula of canagliflozin is shown in Figure 1. PHARMACOKINETICS AND PHARMACODYNAMICS 11,14,17 Canagliflozin is rapidly absorbed in the gastrointestinal (GI) tract. It has a relative oral bioavailability of 65% and reaches peak concentrations within 1 to 2 hours. It can be taken without regard to food, but it is recommended that it be taken before the first meal of the day to allow for the potential to reduce postprandial plasma glucose excursions resulting from delayed intestinal glucose absorption. Canagliflozin is highly protein-bound, mostly to albumin at 99%. The half-lives of 100 mg and 300 mg are 10.6 hours and 13.1 hours, respectively. The drug is metabolized primarily into two inactive metabolites by uridine diphosphate glucuronosyl transferase (UGT) enzymes: UGT 1A9 and UGT 2B4 via glucuronidation. Approximately 7% of the drug also undergoes oxidation via cytochrome Figure 1 Structure of canagliflozin. 656 P&T November 2013 Vol. 38 No. 11
2 P450 (CYP) isoenzymes. Canagliflozin is eliminated largely unchanged in the feces (41.5%) and as metabolites in the urine (30.5%). Removal by dialysis is negligible, and hepatic involvement is minimal. CLINICAL EFFICACY Several phase 2 and phase 3 clinical trials have been conducted to evaluate the efficacy and safety of canagliflozin. Three important studies have been published and may aid in determining the role of canagliflozin in the treatment of type-2 diabetes. Table 1 summarizes the significant findings of each trial. Stenlof et al. 19 A randomized, double-blind, placebocontrolled phase 3 study was conducted to compare the efficacy and safety of canagliflozin and placebo in patients with type- 2 diabetes mellitus that was not controlled with diet and exercise. This multicenter, multinational study enrolled 584 patients between 18 and 80 years of age. Patients had to have one of the following criteria: (1) they were not receiving an antihyperglycemic agent at screening with HbA 1c between 7% and 10%, or (2) they were taking an antihyperglycemic agent as monotherapy (except for a PPAR-g agonist) or metformin and sulfonylurea combination therapy. Patients who were not taking an antihyperglycemic drug underwent a 2-week, single-blind, placebo run-in period. Those who were receiving antihyperglycemic treatment had an 8-week washout and a diet/exercise period, followed by a 2-week placebo run-in phase. All patients then received canagliflozin 100 mg daily, canagliflozin 300 mg daily, or placebo once daily for 26 weeks. The primary endpoint was the change in HbA 1c from baseline. Secondary endpoints included the proportion of patients who achieved HbA 1c below 7%; changes in fasting plasma glucose (FPG) levels, 2-hour postprandial glucose (PPG) levels, and systolic blood pressure (BP); and the percentage of change in body weight, high-density lipoprotein-cholesterol (HDL-C) levels, and triglyceride levels. At 26 weeks, HbA 1c values were significantly reduced with canagliflozin 100 mg daily and 300 mg daily compared with placebo ( 0.77%; 1.03%, and 0.14%, respectively; P < for both canagliflozin groups). Similar reductions in HbA 1c were noted among patients who had not used an antihyperglycemic agent before the study and those who underwent a washout period of anti-hyperglycemic therapy. More patients receiving canagliflozin 100 mg and 300 mg also achieved HbA 1c goals of below 7% (44.5% and 62.4%, respectively) and below 6.5% (17.8% and 28.4%, respectively), compared with patients receiving placebo (20.6% and 5.3%, respectively; P < for both canagliflozin groups). Fewer patients receiving canagliflozin 100 mg and 300 mg (2.6% and 2%, respectively), compared with placebo patients (22.7%), required glycemic rescue therapy. These doses also brought about greater reductions in FPG levels over the 26-week study period; the differences in least-squares mean changes were 2 mmol/l and 2.4 mmol/l, respectively; P < for both canagliflozin groups). Reported differences in least-squares mean changes for 2-hour PPG levels were 2.7 mmol/l with canagliflozin 100 mg and 3.6 mmol/l with 300 mg (P < for both canagliflozin groups). Differences in least-squares mean changes in systolic BP from baseline were also significant at 26 weeks for canagliflozin 100 mg or 300 mg, compared with placebo ( 3.7 mm Hg and 5.4 mm Hg, respectively; P < for both canagliflozin groups). Rapid reductions in body weight were observed during the first 6 weeks of canagliflozin treatment, with progressive decreases seen in patients receiving 300 mg and smaller weight reductions in patients receiving 100 mg over the final 20 weeks of the study. Least-squares mean changes in body weight with both 100 mg and 300 mg were significant compared with placebo ( 1.9 kg and 2.9 kg, respectively; P < for both canagliflozin groups). Statistically significant HDL-C elevations were reported at week 26 (differences in least-squares mean changes of 6.8% for 100 mg and 6.1% for 300 mg vs. placebo; P < for both canagliflozin groups). Nonsignificant reductions in triglyceride levels were also noted for both canagliflozin doses compared with placebo at the end of the treatment period. Adverse events (ADEs) were reported in 61% of patients receiving canagliflozin 100 mg, in 59.9% of patients receiving 300 mg, and in 52.6% of those receiving placebo. Most ADEs were described as mild to moderate in severity. Compared with placebo patients, the canagliflozin treatment groups experienced more genital mycotic infections, urinary tract infections (UTIs), and ADEs associated with osmotic diuresis and reduced intravascular volume. Hypoglycemia was observed in 3.6% of the canagliflozin 100-mg group, in 3% of the 300-mg group, and in 2.6% of the placebo group; no severe cases were reported. One percent of patients in the placebo group and 2.6% of those receiving canagliflozin discontinued treatment because of ADEs. Two deaths (one placebo patient and one patient receiving canagliflozin 100 mg) were reported but were not found to be associated with the treatments. The authors concluded that treatment with canagliflozin in patients with type-2 diabetes that had been inadequately controlled with diet and exercise improved glycemic control, reduced body weight, and was well tolerated. Rosenstock et al. 20 Another randomized, double-blind, placebo-controlled, parallel-group, multicenter, multinational phase 3 study was conducted to evaluate the efficacy and safety of various canagliflozin doses in patients with type-2 diabetes that had not been adequately controlled with metformin. Eligibility criteria included patients 18 to 65 years of age with type-2 diabetes for a period of at least 3 months; HbA 1c level of 7% or higher; 10.5% or fewer receiving metformin alone for 3 months or more at a dose of 1,500 mg/day or higher; a body mass index (BMI) of 25 to 45 kg/m 2 (24 to 45 kg/m 2 for Asian descendants); and serum creatinine levels below 1.5 mg/dl for men and below 1.4 mg/dl for women. Patients (n = 451) received canagliflozin 50, 100, 200, or 300 mg once daily; canagliflozin 300 mg twice daily; or placebo. An arm receiving sitagliptin (Januvia, Merck) 100 mg once daily was also included as an active-reference treatment group but was not compared with the canagliflozin groups. All patients underwent a 3- to 4-week pretreatment screening phase, followed by a 12-week treatment phase and a 2-week post-treatment phase. The primary endpoint was the change in HbA 1c from baseline to the completion of treatment. The secondary endpoints Vol. 38 No. 11 November 2013 P&T 657
3 Table 1 Evaluating the Use of Canagliflozin in Type-2 Diabetes: Significant Findings From Three Clinical Trials Study Endpoints Results Stenlof et al. 19 Primary: a 1. Change in HbA 1c Canagliflozin 100 mg daily: 0.77% b Canagliflozin 300 mg daily: 1.03% b Placebo 0.14% Secondary: a 1. Proportion of patients who achieved HbA 1c < 7% 2. Change in FPG 3. Change in 2-hour PPG 4. Change in systolic BP 5. Change in body weight 6. Change in HDL-C Canagliflozin 100 mg daily: 44.5% b Canagliflozin 300 mg daily: 62.4% b Placebo: 20.6% Canagliflozin 100 mg daily: 1.5 mmol/l b,c Canagliflozin 300 mg daily: 1.9 mmol/l b,c Placebo: 0.5 mmol/l Canagliflozin 100 mg daily: 2.4 mmol/l b,c Canagliflozin 300 mg daily: 3.3 mmol/l b,c Placebo: 0.3 mmol/l Canagliflozin 100 mg daily: 3.3 mm Hg b,c Canagliflozin 300 mg daily: 5 mm Hg b,c Placebo: 0.4 mmhg Canagliflozin 100 mg daily: 2.5 kg b,c Canagliflozin 300 mg daily: 3.4 kg b,c Placebo: 0.5 kg Canagliflozin 100 mg daily: 11.2% b,c Canagliflozin 300 mg daily: 10.6% c,d Placebo: 4.5% Rosenstock et al. 20 Primary: e Change in HbA 1c Secondary: e 1. Percentage of patients who achieved HbA 1c < 7% 2. Percentage of patients who achieved HbA 1c < 6.5% 3. Change in FPG 0.79%, b 0.76%, b 0.70%, b and 0.92% b (respectively) Canagliflozin 300 mg twice daily: 0.95% b Sitagliptin 100 mg daily: 0.74% b Placebo: 0.22% Canagliflozin > 100 mg daily: 53% 72% f Sitagliptin 100 mg daily: 65% f Placebo: 34% Canagliflozin > 100 mg daily: 27% 42% f Sitagliptin 100 mg daily: 45% f Placebo: 13% 16.2 mg/dl, b 25.2 mg/dl, b 27 mg/dl, b and 25.2 mg/dl b (respectively) Canagliflozin 300 mg twice daily: 23.4 mg/dl b Sitagliptin 100 mg daily: 12.6 mg/dl Placebo: 3.6 mg/dl 658 P&T November 2013 Vol. 38 No. 11
4 Table 1 Evaluating the Use of Canagliflozin in Type-2 Diabetes: Significant Findings From Three Clinical Trials (continued) Study Endpoints Results Rosenstock 4. Mean weight reduction et al kg, b 2.6 kg, b 2.7 kg, b and 3.4 kg b (respectively) continued Canagliflozin 300 mg twice daily: 3.4 kg b Sitagliptin 100 mg daily: 0.6 kg Placebo: 1.1 kg Schernthaner et al Change in UGC ratio Primary: g Change in HbA 1c 1. Percentage of patients who achieved HbA 1c < 7% 2. Percentage of patients who achieved HbA 1c < 6.5% Secondary: g 1. Changes in FPG 2. Change in systolic BP 3. Change in body weight 4. Change in HDL-C 35.4 mg/mg, b 51.5 mg/mg, b 50.5 mg/mg, b and 49.4 mg/mg b (respectively) Canagliflozin 300 mg twice daily: 61.6 mg/mg b Sitagliptin 100 mg daily: 1.9 mg/mg Placebo: 1.9 mg/mg Canagliflozin 300 mg daily: 1.03% c,h Sitagliptin 100 mg daily: 0.66% Canagliflozin 300 mg daily: 47.6% c,h Sitagliptin 100 mg daily: 35.3% Canagliflozin 300 mg daily: 22.5 % c,h Sitagliptin 100 mg daily: 18.8% Canagliflozin 300 mg daily: 28.7 mg/dl c,h Sitagliptin 100 mg daily: 2.2 mg/dl Canagliflozin 300 mg daily: 5.1 mm Hg c,h Sitagliptin 100 mg daily: 0.9 mm Hg Canagliflozin 300 mg daily: 2.3 kg c,h Sitagliptin 100 mg daily: 0.1 kg Canagliflozin 300 mg daily: 7.6% c,h Sitagliptin 100 mg daily: 0.6% BP = blood pressure; FGP = fasting plasma glucose; HBA 1c = glycosylated hemoglobin; HDL-C = high-density lipoprotein-cholesterol; PPG = postprandial glucose; UGC = urinary glucose-to-creatinine. a Results at 26 weeks (from baseline). b P < 0.001, compared with placebo. c Least-squares mean change. d P < 0.01, compared with placebo. e Results at 12 weeks (from baseline). f P < 0.05, compared with placebo. g Results at 52 weeks (from baseline). h P < 0.001, compared with sitagliptin. included the change in the percentage of patients who achieved HbA 1c below 7% and below 6.5% and changes in FPG, body weight, and an overnight urinary glucose-to-creatinine (UGC) ratio after 12 weeks. Forty-nine patients discontinued treatment before the end of the 12-week period. A similar number of patients in all treatment arms discontinued therapy. At 12 weeks, efficacy analyses revealed significant changes in HbA 1c from baseline for canagliflozin 50, 100, 200, or 300 mg once daily and canagliflozin 300 mg twice daily compared with placebo ( 0.79%, 0.76%, 0.70%, 0.92%, 0.95% and 0.22%, respectively; P < for all canagliflozin doses), with a 0.74% reduction for the sitagliptin arm (P < vs. placebo). Fifty-three to 72% of patients who received 100 mg or more of canagliflozin and 65% of those who received sitagliptin achieved HbA 1c values below 7%, compared with 34% of those in the placebo group. HbA 1c values below 6.5% were also achieved by 27%, 42%, and 32% of patients receiving canagliflozin 100 and 300 mg once daily and 300 mg twice daily, Vol. 38 No. 11 November 2013 P&T 659
5 respectively, as well as 45% of those who received sitagliptin, compared with the placebo group (13%). Significant and greater mean reductions in FPG levels were noted for all canagliflozin groups at 3 weeks and were maintained throughout the 12-week treatment period (16.2, 25.2, 27, 25.2, and 23.4 mg/ dl, respectively, vs. 3.6 mg/dl in the placebo group; P < for all canagliflozin doses). Sitagliptin reduced FPG levels by 12.6 mg/dl, but the change was not statistically significant compared with placebo. At week 12, changes in body weight and UGC ratios were also statistically significant, compared with placebo. Mean weight reductions from baseline for canagliflozin subjects were 2.3, 2.6, 2.7, 3.4, and 3.4 kg, respectively, compared with 1.1 kg for placebo. A weight reduction of 0.6 kg was also seen in the sitagliptin patients, but this change was not statistically significant when compared with placebo. Increases in UGC ratios were reported for all canagliflozin patients (35.4, 51.5, 50.5, 49.4, and 61.6 mg/mg) and were significantly greater than for placebo patients (1.9 mg/mg; P < 0.001). The sitagliptin patients experienced reductions in the UGC ratio ( 1.9 mg/mg). HDL-C levels were significantly increased with canagliflozin 300 mg twice daily, and triglyceride levels were significantly reduced with 300 mg once daily and twice daily, compared with placebo (P < 0.001, P = 0.025, and P = 0.001, respectively). ADEs were reported in 26% to 56% of canagliflozin patients, 35% of sitagliptin patients, and 40% of placebo patients. Most ADEs were described as mild to moderate in severity. Nine canagliflozin patients and two placebo patients discontinued therapy because of ADEs, mainly gastrointestinal disorders. Compared with the placebo group, patients receiving the study drug experienced more genital infections (2% vs. 3 8%, respectively), particularly in female patients (3% vs. 13% 25%, respectively). Low and similar incidences of hypoglycemia, UTIs, polyuria (excess diuresis), pollakiuria (abnormal frequency of urination) and hypovolemia-associated ADEs were observed among all study participants. Small reductions in systolic BP were also noted with canagliflozin treatment. (Polyuria can be associated with diabetes; 660 P&T November 2013 Vol. 38 No. 11 pollakiuria is thought to be associated with psychological stress.) The authors concluded that the addition of canagliflozin treatment to inadequate metformin monotherapy in patients with type-2 diabetes was relatively well tolerated and resulted in significant improvement of glycemic control while yielding favorable effects on body weight, HDL-C levels, and triglyceride levels. Schernthaner et al. 21 In a 52-week, randomized, doubleblind, active-controlled, phase 3 study, the efficacy and safety of canagliflozin were evaluated and compared with sitagliptin in patients with type-2 diabetes who were not responding adequately to metformin and sulfonylurea therapy. This multicenter, multinational trial enrolled patients 18 years of age or older with type- 2 diabetes who were following a stable regimen of metformin (1,500 mg/day or higher) and a sulfonylurea (half-maximal daily doses or more) and HbA 1c values between 7% and 10.5%. Eligible patients underwent a singleblind 2-week placebo run-in period, followed by double-blind randomization to receive either canagliflozin 300 mg once daily or sitagliptin 100 mg once daily. A 4-week post-treatment period followed the 52-week treatment period. The primary endpoint was the change in HbA 1c from baseline to week 52. Secondary endpoints included changes in systolic BP; body weight; and FPG, HDL-C, and triglyceride levels. The authors analyzed non-inferiority between the treatment groups, but they also evaluated superiority if non-inferiority was determined. Of the 756 patients initially assigned to active-treatment, 464 completed the 52-week treatment period and were included in the efficacy and safety analyses. Approximately 33% of the canagliflozin group and 44% of the sitagliptin group stopped therapy because of the need for glycemic rescue therapy, elevated creatinine levels (>1.4 for men or 1.3 for women), estimated glomerular filtration rate (egfr) (<55 60 ml/minute/1.73 m 2, depending on labeling national labeling of metformin), or intolerable ADEs. At the end of 52 weeks, canagliflozin 300 mg daily was found to be noninferior to sitagliptin 100 mg daily in terms of HbA 1c changes from baseline, with least-squares mean changes of 1.03% and 0.66%, respectively. Differences in least-squares means were 0.37% (95% confidence interval [CI], 0.5 to 0.25). Further analysis revealed that canagliflozin was also superior to sitagliptin in reducing HbA 1c values, and more canagliflozin patients achieved HbA 1c goals of less than 7% (47.6% vs. 35.3%, respectively) and less than 6.5% (22.5% vs. 18.8%, respectively). At the end of the treatment period, reductions in FPG levels were greater among patients who received canagliflozin than those who received sitagliptin. Least-squares mean changes were 28.7 mg/dl and 2.2 mg/dl, respectively. The difference in least-squares means was 5.9 mm Hg (P < 0.001). Systolic BP was also significantly reduced with canagliflozin compared with sitagliptin ( 5.1 vs. 0.9 mm Hg, respectively). The difference in least-squares means was 5.9 mm Hg (P < 0.001). Canagliflozin patients experienced significantly greater weight loss than the sitagliptin group. Least-squares mean changes were 2.3 kg and 0.1 kg, respectively; the difference in least-squares means was 2.4 kg (P < 0.001). Elevations in HDL-C were also significantly greater with canagliflozin than with sitagliptin. Least-squares mean changes were 7.6% and 0.6%, respectively; the difference in least-squares means was 7% (95% CI, ). Similar modest elevations in triglycerides and low-density lipoprotein-cholesterol (LDL-C) were also noted, with statistically significant greater elevations in LDL-C with canagliflozin (11.7% vs. 5.2%, respectively); the difference in least-squares means was 6.4% (95% CI, ). The incidence of ADEs was similar for both treatment groups. A higher rate of genital mycotic infections in females and one discontinuation of canagliflozin were reported at the end of the study. Fewer than 2% of canagliflozin ADEs were associated with osmotic diuresis (e.g., thirst and pollakiuria). Similar incidences of hypoglycemia and UTIs were observed in both the canagliflozin and sitagliptin groups. The authors concluded that canagliflozin provided greater glycemic control and weight reductions than sitagliptin, but it resulted in more mycotic infections in patients with type-2 diabetes who had received metformin and sulfonylurea therapy. continued on page 665
6 continued from page 660 ADVERSE DRUG REACTIONS 17,19 21 In clinical trials, canagliflozin was generally associated with a higher incidence of genital mycotic infections, UTIs, increased urination, and ADEs associated with osmotic diuresis and reduced intravascular volume. Uncircumcised men and both men and women with a history of genital mycotic infections were predisposed to recurrent mycotic genital infections requiring oral or topical antifungal treatment and antimicrobial therapy. Decreases in egfr, serum urate, alanine aminotransferase (ALT), gamma-glutamyl transferase (GGT), and alkaline phosphatase levels have also been observed in patients treated with canagliflozin, in addition to increases in serum creatinine, blood urea nitrogen, hemoglobin, hematocrit, and bilirubin compared with placebo and other active treatments. INDICATIONS AND USAGE 17 Canagliflozin is approved for adults with type-2 diabetes mellitus who require improved glycemic control in addition to diet and exercise. This drug has not been studied and is not recommend for patients with type-1 diabetes mellitus or diabetic ketoacidosis. DRUG INTERACTIONS 17 UGT enzyme inducers (e.g., rifampin, phenytoin, ritonavir)may decrease the plasma levels ans efficacy of canagliflozin. The canagliflozin dose can be increased to 300 mg once daily (1) in patients with an egfr exceeding 60 ml/minute/1.73 m 2, (2) in those requiring a UGT enzyme inducer and additional glycemic control, and (3) in those currently tolerating a dose of 100 mg once daily. Alternative antihyperglycemic agents are suggested in patients with an egfr of 45 to 60 ml/ minute/1.72 m 2 who require additional glycemic management. There appear to be no significant interactions between canagliflozin and CYP450 enzymes 1A2, 2A6, 3A4, 2B6, 2C9, 2C19, 2D6, and 2E1. Digoxin plasma concentrations may be increased with the concomitant administration of canagliflozin; therefore, monitoring is advised. CONTRAINDICATIONS 17 Canagliflozin is contraindicated in patients with a severe hypersensitivity reaction to the drug, in individuals with severe renal impairment (an egfr below 30 ml/minute/ ), in those with endstage renal disease, and in patients on dialysis. PRECAUTIONS AND WARNINGS 17 Volume status should be assessed and corrected before canagliflozin is initiated in patients with low BP, in those using diuretics or drugs that interfere with the renin angiotensin aldosterone system (RAS), or in those with impaired renal function. Symptomatic hypotension was observed more frequently in patients receiving the 300-mg dose, in those with impaired renal function, in those receiving loop diuretics, and in people 75 years of age or older. Caution is warranted if the egfr is below 60 ml/minute/1.73 m 2. Frequent monitoring of renal function is recommended during the initiation of therapy. Monitoring of serum potassium levels is also recommended upon the initiation of canagliflozin therapy in patients with renal impairment and in those taking medications that can interfere with potassium secretion to avoid the risk of hyperkalemia. Prescribers should also exercise caution for patients who are using insulin or insulin secretagogues. Dose adjustments of the insulin or insulin secretagogues may be needed to avoid hypoglycemia. Patients taking canagliflozin should be informed about and monitored for signs and symptoms of genital mycotic infections. Uncircumcised males and patients with a history of genital mycotic infections may be at increased risk and may require treatment. It is also recommended that LDL-C levels be monitored, as dose-related increases in LDL-C levels have been observed with this medication. Canagliflozin has been designated as a Pregnancy Category C drug. Well-controlled studies have not been conducted in pregnant women, and it is unknown whether this medication is excreted in human milk. There is no evidence to support its use in lactation. DOSAGE AND ADMINISTRATION 17 The recommended starting dose of canagliflozin is 100 mg once daily before the first meal. Patients who need additional glycemic control can increase the dose to 300 mg once daily if the 100-mg dose was well tolerated and the egfr was 60 ml/minute/1.73 m 2 or greater. The dose should not exceed 100 mg once daily in patients with moderate renal impairment (egfr, ml/minute/1.73 m 2 ), and therapy should not be initiated if the egfr is below 45 ml/minute/1.73 m 2. COST 22 Canagliflozin (Invokana) is sold as 100-mg film-coated, yellow capsuleshaped tablets and as 300-mg film-coated, white capsule-shaped tablets. According to the 2013 edition of Red Book, the average wholesale price of a bottle of 30 tablets (100 mg or 300 mg) is $236.10, and a bottle of 90 tablets (100 mg or 300 mg) is $ CONCLUSION Treatment options for type-2 diabetes are often limited by the degree of glycemic control provided and by safety profiles. Canagliflozin is a novel agent that may aid in achieving glycemic goals in many patients with type-2 diabetes who are also following diet and exercise regimens and who have not responded adequately to other antihyperglycemic agents. This drug is generally well tolerated and may yield additional favorable effects, for example, on BP and body weight. REFERENCES 1. Number (in millions) of civilian, noninstitutionalized persons with diagnosed diabetes, United States, CDC Data Sheet. Available at: Accessed June 24, Centers for Disease Control and Prevention (CDC). National Diabetes Fact Sheet, Available at: Accessed June 20, Boyle JP, Thompson TJ, Gregg EW, et al. Projection of the year 2050 burden of diabetes in the U.S. adult population: Dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr 2010;8: Diagnosis and classification of diabetes mellitus. Diabetes Care 2013;36(Suppl 1);S67 S Nguyen NT, Nguyen XM, Lane J, Wang P. Relationship between obesity and diabetes in a U.S. adult population: Findings from the National Health and Nutrition Examination survey, Obes Surg 2011;21: Economic costs of diabetes in the U.S. in Diabetes Care 2013;36: American Diabetes Association. Standards of medical care in diabetes Diabetes Care 2013;36(Suppl 1);S11 S Stark Casagrande S, Fradkin JE, Saydah SH. The prevalence of meeting A 1c, blood pressure, and LDL goals among people Vol. 38 No. 11 November 2013 P&T 665
7 with diabetes, Diabetes Care, February 15, 2013 (online). 9. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: Patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35: Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE Comprehensive diabetes management algorithm. Endocr Pract 2013;19(2): Nomura S, Sakamaki S, Hongu M, et al. Discovery of canagliflozin, a novel c-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus. J Med Chem 2010;53: Valentine V. The role of the kidney and sodium-glucose co-transporter-2 inhibition in diabetes management. Clin Diabetes 2012:30; FDA approves Invokana to treat type 2 diabetes: First in a new class of diabetes drugs. March 29, Available at: PressAnnouncements/Ucm htm. Accessed May 20, Neumiller JJ, White JR Jr, Campbell RK. Sodium-glucose co-transport inhibitors: Progress and therapeutic potential in type 2 diabetes mellitus. Drugs 2010;70: Kim Y, Babu AR. Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes. Diabetes Metab Syndr Obes 2012;5: Idris I, Donnelly R. Sodium-glucose cotransporter-2 inhibitors: An emerging new class of oral antidiabetic drug. Diabetes Obes Metab 2009;11(2): Invokana (canagliflozin), prescribing information. Titusville, N.J.: Janssen; March AMCP Dossier Invokana (canagliflozin). Titusville, N.J.: Janssen MedInfo; April 15, Stenlof K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013;15: Rosenstock J, Aggarwal N, Polidori D, et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotranstporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012; 35: Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea. Diabetes Care 2013;36(19): Red Book Online Available at: www. micromedexsolutions.com. Accessed July 1, n 666 P&T November 2013 Vol. 38 No. 11
嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯
The Clinical Efficacy and Safety of Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors in Adults with Type 2 Diabetes Mellitus 嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯 Diabetes Mellitus : A group of diseases characterized
More informationSecond- and Third-Line Approaches for Type 2 Diabetes Workgroup: Topic Brief
Second- and Third-Line Approaches for Type 2 Diabetes Workgroup: Topic Brief March 7, 2016 Session Objective: The objective of this workshop is to assess the value of undertaking comparative effectiveness
More informationHarmony Clinical Trial Medical Media Factsheet
Overview Harmony is the global Phase III clinical trial program for Tanzeum (albiglutide), a product developed by GSK for the treatment of type 2 diabetes. The comprehensive program comprised eight individual
More informationINSIDE FROM THE DESK OF THE PRESIDENT. Volume 23, No. 5 September/October 2013
Editor: Dana Jamero djamero@xula.edu www.lshp.org Volume 23, No. 5 September/October 2013 FROM THE DESK OF THE PRESIDENT Dear Members, I am pleased to report that your Executive Committee and Board has
More informationClinical Assistant Professor. Clinical Pharmacy Specialist Wesley Family Medicine Residency Program. Objectives
What s New in Diabetes Medications? Matthew Kostoff, PharmD, BCPS, BCACP Clinical Assistant Professor Clinical Pharmacy Specialist Wesley Family Medicine Residency Program Objectives Discuss new literature
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Afrezza Page 1 of 6 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Afrezza (human insulin) Prime Therapeutics will review Prior Authorization requests Prior Authorization
More informationCASE A1 Hypoglycemia in an Elderly T2DM Patient with Heart Failure
Hypoglycemia in an Elderly T2DM Patient with Heart Failure 1 I would like to introduce you to Sophie, an elderly patient with long-standing type 2 diabetes, who has a history of heart failure, a common
More informationReference ID: 3817663
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See full prescribing information for. (canagliflozin) tablets, for oral use
More informationReference ID: 3907892
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use INVOKANA safely and effectively. See full prescribing information for INVOKANA. INVOKANA (canagliflozin)
More informationINVOKAMET (canagliflozin and metformin hydrochloride) tablets for oral use
INVOKAMET (canagliflozin and metformin hydrochloride) tablets for oral use Revised: 05/2016 053644-160523 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed
More informationtrends in the treatment of Diabetes type 2 - New classes of antidiabetic drugs. IAIM, 2015; 2(4): 223-
Review Article Pharmacological trends in the treatment of Diabetes type 2 - New classes of antidiabetic Silvia Mihailova 1*, Antoaneta Tsvetkova 1, Anna Todorova 2 1 Assistant Pharmacist, Education and
More informationHypoglycemics, Metformins Therapeutic Class Review (TCR)
Hypoglycemics, Metformins Therapeutic Class Review (TCR) December 19, 2013 The literature review is current through February 22, 2016. No part of this publication may be reproduced or transmitted in any
More informationType 2 Diabetes Update For 2015
Type 2 Diabetes Update For 2015 Jerry Meece, RPh, CDE, FACA, FAADE Plaza Pharmacy and Wellness Center jmeece12@cooke.net Learning Objectives At the conclusion of this presentation, the participant will
More informationTYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION. Robert Dobbins, M.D. Ph.D.
TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION Robert Dobbins, M.D. Ph.D. Learning Objectives Recognize current trends in the prevalence of type 2 diabetes. Learn differences between type 1 and type
More informationJARDIANCE (empagliflozin) tablets, for oral use Initial U.S. Approval: 2014
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use JARDIANCE safely and effectively. See full prescribing information for JARDIANCE. JARDIANCE (empagliflozin)
More informationINVOKANA (canagliflozin) tablets, for oral use
(canagliflozin) tablets, for oral use Revised: 12/2015 044378-151208 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See
More informationlinagliptin, 5mg film-coated tablet (Trajenta ) SMC No. (746/11) Boehringer Ingelheim / Eli Lilly and Company Ltd
linagliptin, 5mg film-coated tablet (Trajenta ) SMC No. (746/11) Boehringer Ingelheim / Eli Lilly and Company Ltd 09 December 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of
More informationDavid Shu, MD, FRCPC Endocrinology, Royal Columbian Hospital October 8 th, 2010
David Shu, MD, FRCPC Endocrinology, Royal Columbian Hospital October 8 th, 2010 Objectives At the end of the talk, the participants will be able to: 1. Identify the increasing prevalence of type 2 diabetes
More informationPharmaceutical Management of Diabetes Mellitus
1 Pharmaceutical Management of Diabetes Mellitus Diabetes Mellitus (cont d) Signs and symptoms 2 Elevated fasting blood glucose (higher than 126 mg/dl) or a hemoglobin A1C (A1C) level greater than or equal
More informationType II diabetes: How to use the new oral medications
Type II diabetes: How to use the new oral medications A TWO-PART INTERVIEW WITH NANCY J.V. BOHANNON, MD, BY DAVID B. JACK, MD Several new oral drugs have been approved for the management of type II diabetes.
More informationImeglimin: A Potential New Multi-Target Drug for Type 2 Diabetes
Drugs R D (2015) 15:227 232 DOI 10.1007/s40268-015-0099-3 REVIEW ARTICLE Imeglimin: A Potential New Multi-Target Drug for Type 2 Diabetes Valerie Vuylsteke 1 Lisa M. Chastain 2 Geeta A. Maggu 3 Crystal
More informationStrengthening the Pharmacist Skills in Managing Diabetes Practice Based Program 27 Contact Hours
Strengthening the Pharmacist Skills in Managing Diabetes Practice Based Program 27 Contact Hours Presented by New York State Council of Health system Pharmacists October 18 19, 2013 St. John s University,
More informationEFFIMET 1000 XR Metformin Hydrochloride extended release tablet
BRAND NAME: Effimet XR. THERAPEUTIC CATEGORY: Anti-Diabetic PHARMACOLOGIC CLASS: Biguanides EFFIMET 1000 XR Metformin Hydrochloride extended release tablet COMPOSITION AND PRESENTATION Composition Each
More informationVolume 01, No. 08 November 2013
State of New Jersey Department of Human Services Division of Medical Assistance & Health Services New Jersey Drug Utilization Review Board Volume 01, No. 08 November 2013 TO: SUBJECT: PURPOSE: Physicians,
More informationNovel Trial Designs in T2D to Satisfy Regulatory Requirements for CV Safety
Novel Trial Designs in T2D to Satisfy Regulatory Requirements for CV Safety Anders Svensson MD, PhD Head of Global Clinical Development Metabolism, F Hoffmann LaRoche Ltd. Basel, Switzerland Overview of
More informationCME Test for AMDA Clinical Practice Guideline. Diabetes Mellitus
CME Test for AMDA Clinical Practice Guideline Diabetes Mellitus Part I: 1. Which one of the following statements about type 2 diabetes is not accurate? a. Diabetics are at increased risk of experiencing
More informationCASE B1. Newly Diagnosed T2DM in Patient with Prior MI
Newly Diagnosed T2DM in Patient with Prior MI 1 Our case involves a gentleman with acute myocardial infarction who is newly discovered to have type 2 diabetes. 2 One question is whether anti-hyperglycemic
More informationGUIDELINES FOR THE TREATMENT OF DIABETIC NEPHROPATHY*
71 GUIDELINES FOR THE TREATMENT OF DIABETIC NEPHROPATHY* Ryuichi KIKKAWA** Asian Med. J. 44(2): 71 75, 2001 Abstract: Diabetic nephropathy is the most devastating complication of diabetes and is now the
More informationGlucagon Receptor Antagonist: LGD-6972 Program Overview and Phase 1b Results
Glucagon Receptor Antagonist: LGD-6972 Program Overview and Phase 1b Results American Diabetes Association s 75th Scientific Sessions June 7, 2015 Boston 2 Safe Harbor Statement The following presentation
More informationDiabetes Mellitus. Melissa Meredith M.D. Diabetes Mellitus
Melissa Meredith M.D. Diabetes mellitus is a group of metabolic diseases characterized by high blood glucose resulting from defects in insulin secretion, insulin action, or both Diabetes is a chronic,
More informationWelchol (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes
For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Takashi Shoda, President and Representative Director (Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)
More informationTable 1. Ominous Octet and Medications to Target Defects Origin of Defect Pathophysiologic Defect Medication Class Targeting Defect
Canagliflozin: A Novel Agent for the Treatment of Type 2 Diabetes Mellitus By Marquita D. Bradshaw, Pharm.D., BCACP and Rikki L. Tonet, Pharm.D. Candidate 2014 Objectives Describe the pathophysiological
More informationJARDIANCE (empagliflozin) tablets, for oral use Initial U.S. Approval: 2014
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See full prescribing information for. (empagliflozin) tablets, for oral use
More informationTreating Patients with PRE-DIABETES David Doriguzzi, PA-C First Valley Medical Group. Learning Objectives. Background. CAPA 2015 Annual Conference
Treating Patients with PRE-DIABETES David Doriguzzi, PA-C First Valley Medical Group Learning Objectives To accurately make the diagnosis of pre-diabetes/metabolic syndrome To understand the prevalence
More informationDiabetes Mellitus 1. Chapter 43. Diabetes Mellitus, Self-Assessment Questions
Diabetes Mellitus 1 Chapter 43. Diabetes Mellitus, Self-Assessment Questions 1. A 46-year-old man presents for his annual physical. He states that he has been going to the bathroom more frequently than
More information4/23/2015. Conflict of Interest Disclosure
Endocrine/Diabetes Pharmacology Review May 8, 2015 Chris Winslow, PharmD, MBA and Amanda Brown, PharmD Conflict of Interest Disclosure A conflict of interest exists when an individual is in a position
More informationIMPROVED METABOLIC CONTROL WITH A FAVORABLE WEIGHT PROFILE IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH INSULIN GLARGINE (LANTUS ) IN CLINICAL
464 IMPROVED METABOLIC CONTROL WITH A FAVORABLE WEIGHT PROFILE IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH INSULIN GLARGINE (LANTUS ) IN CLINICAL PRACTICE STEPHAN A SCHREIBER AND ANIKA RUßMAN ABSTRACT
More informationNCT00272090. sanofi-aventis HOE901_3507. insulin glargine
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Generic drug name:
More informationComparing Medications for Adults With Type 2 Diabetes Focus of Research for Clinicians
Clinician Research Summary Diabetes Type 2 Diabetes Comparing Medications for Adults With Type 2 Diabetes Focus of Research for Clinicians A systematic review of 166 clinical studies published between
More informationSponsor. Novartis Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Investigational.
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Investigational Study Number CLAF237A2386 Title A single-center,
More informationDosage adjustment is recommended for patients with moderate or severe renal insufficiency or end-stage renal disease. (2.2)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use JANUVIA safely and effectively. See full prescribing information for JANUVIA. JANUVIA (sitagliptin)
More informationDiabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria.
Kidney Complications Diabetic Nephropathy Diabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria. The peak incidence of nephropathy is usually 15-25 years
More informationInsulin myths and facts
london medicines evaluation network Insulin myths and facts Statement 1 Insulin is the last resort for patients with Type 2 diabetes After initial metformin and sulfonylurea therapy, NICE and SIGN suggest
More informationTuberculosis And Diabetes. Dr. hanan abuelrus Prof.of internal medicine Assiut University
Tuberculosis And Diabetes Dr. hanan abuelrus Prof.of internal medicine Assiut University TUBERCULOSIS FACTS More than 9 million people fall sick with tuberculosis (TB) every year. Over 1.5 million die
More informationTargeting the Kidney. Renal Glucose Transport 11/4/2015. Non insulin Agents Available IBITORS. Chao EC, et al. Nat Rev Drug Discovery. 2010;9:551 559.
SGLT-2i and DPP-IVi in the Management of Diabetes Mellitus Type 2 Abel Alfonso, D.O., F.A.C.E. Endocrinologist November 5, 2015 DIABETES: CURRENT RATES AND PROJECTIONS CDC Press Release 2010: 1 in 3 adults
More informationJANUVIA sitagliptin phosphate 25 mg, 50 mg & 100 mg tablets
JANUVIA sitagliptin phosphate 25 mg, 50 mg & 100 mg tablets What is in this leaflet This leaflet answers some common questions about JANUVIA. It does not contain all the available information. It does
More informationClinical Efficacy of Gliptins for Glycemic Control in Type 2 Diabeties Mellitus
World Applied Sciences Journal 7 (1): 01-06, 2009 ISSN 1818-4952 IDOSI Publications, 2009 REVIEW ARTICLE Clinical Efficacy of Gliptins for Glycemic Control in Type 2 Diabeties Mellitus 1 2 3 1 2 Atif Sitwat
More informationTake a moment Confer with your neighbour And try to solve the following word picture puzzle slides.
Take a moment Confer with your neighbour And try to solve the following word picture puzzle slides. Example: = Head Over Heels Take a moment Confer with your neighbour And try to solve the following word
More informationBaskets of Care Diabetes Subcommittee
Baskets of Care Diabetes Subcommittee Disclaimer: This background information is not intended to be a comprehensive scientific discussion of the topic, but rather an attempt to provide a baseline level
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationDIABETES MELLITUS GUIDELINES
DIABETES MELLITUS GUIDELINES Virginia Premier Health Plan Virginia Premier Health Plan, Clinical Practice Guideline-Diabetes 1. Population screening a. Indications i. Adults of any age with body mass index
More informationOverview of Diabetes Management. By Cindy Daversa, M.S.,R.D.,C.D.E. UCI Health
Overview of Diabetes Management By Cindy Daversa, M.S.,R.D.,C.D.E. UCI Health Objectives: Describe the pathophysiology of diabetes. From a multiorgan systems viewpoint. Identify the types of diabetes.
More informationDipeptidyl Peptidase-IV Inhibitors: A New Drug in the Therapeutic Armamentarium for Treatment of Type 2 Diabetes Mellitus
REVIEW ARTICLE JIACM 2009; 10(3): 128-33 Dipeptidyl Peptidase-IV Inhibitors: A New Drug in the Therapeutic Armamentarium for Treatment of Type 2 Diabetes Mellitus Rajesh Rajput* Introduction The incidence
More informationTeriflunomide is the active metabolite of Leflunomide, a drug employed since 1994 for the treatment of rheumatoid arthritis (Baselt, 2011).
Page 1 of 10 ANALYTE NAME AND STRUCTURE TERIFLUNOMIDE Teriflunomide TRADE NAME Aubagio CATEGORY Antimetabolite TEST CODE PURPOSE Therapeutic Drug Monitoring GENERAL RELEVANCY BACKGROUND sclerosis. The
More informationTYPE 2 DIABETES IN CHILDREN DIAGNOSIS AND THERAPY. Ines Guttmann- Bauman MD Clinical Associate Professor, Division of Pediatric Endocrinology, OHSU
TYPE 2 DIABETES IN CHILDREN DIAGNOSIS AND THERAPY Ines Guttmann- Bauman MD Clinical Associate Professor, Division of Pediatric Endocrinology, OHSU Objectives: 1. To discuss epidemiology and presentation
More informationAdult Diabetes Clinician Guide
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Adult Diabetes Clinician Guide Introduction JANUARY 2016 This evidence-based guideline summary is based on the 2016 National Diabetes Guideline.
More informationDiabetes mellitus. Lecture Outline
Diabetes mellitus Lecture Outline I. Diagnosis II. Epidemiology III. Causes of diabetes IV. Health Problems and Diabetes V. Treating Diabetes VI. Physical activity and diabetes 1 Diabetes Disorder characterized
More informationEffect of liraglutide on body weight in overweight or obese subjects with type 2 diabetes: SCALE - Diabetes
Effect of liraglutide on body weight in overweight or obese subjects with type 2 diabetes: SCALE - Diabetes This trial is conducted in Africa, Asia, Europe and the United States of America (USA). The aim
More informationDiabetes Dispatch. Identify appropriate treatment options in pregnant women diagnosed with gestational
A L A S K A N A T I V E D I A B E T E S T E A M Diabetes Dispatch Volume 8, Issue 2 Summer 2013 Gestational Diabetes Compiled by Danielle Clare Pharm.D. Candidate 2014 Diabetes continues to be a health
More informationINSULIN TREATMENT FOR TYPE 2 DIABETES MANAGEMENT
INSULIN TREATMENT FOR TYPE 2 DIABETES MANAGEMENT APIRADEE SRIWIJITKAMOL DIVISION OF ENDOCRINOLOGY AND METABOLISM DEPARTMENT OF MEDICINE FACULTY OF MEDICINE SIRIRAJ HOSPITOL QUESTION 1 1. ท านเคยเป นแพทย
More informationCOST ANALYSIS OF ANTIDIABETIC DRUGS FOR DIABETES MELLITUS OUTPATIENT IN KODYA YOGYAKARTA HOSPITAL
Malaysian Journal of Pharmaceutical Sciences, Vol. 5, No. 1, 19 23 (2007) COST ANALYSIS OF ANTIDIABETIC DRUGS FOR DIABETES MELLITUS OUTPATIENT IN KODYA YOGYAKARTA HOSPITAL TRI MURTI ANDAYANI* AND IKE IMANINGSIH
More informationNursing 113. Pharmacology Principles
Nursing 113 Pharmacology Principles 1. The study of how drugs enter the body, reach the site of action, and are removed from the body is called a. pharmacotherapeutics b. pharmacology c. pharmacodynamics
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PC - Apidra, Levemir Therapeutic Class: Hormones and Synthetic Substitutes Therapeutic Sub-Class: Antidiabetic Agents Client: CA, CO, NV, OK, OR, WA and AZ Approval
More informationTreatment of Type 2 Diabetes
Improving Patient Care through Evidence Treatment of Type 2 Diabetes This information is based on a comprehensive review of the evidence for best practices in the treatment of type 2 diabetes and is sponsored
More informationMetabolic acidosis, including diabetic ketoacidosis. (4, 5.1)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use XIGDUO XR safely and effectively. See full prescribing information for XIGDUO XR. XIGDUO XR (dapagliflozin
More informationAdvances in T2D Treatment: Elevating Management in the Primary Care Setting with New Therapeutic Options
Saturday General Session Advances in T2D Treatment: Elevating Management in the Primary Care Setting with New Therapeutic Options Charles Reasner II, MD Staff Physician, Diabetes America Adjunct Professor
More informationNutrition. Type 2 Diabetes: A Growing Challenge in the Healthcare Setting NAME OF STUDENT
1 Nutrition Type 2 Diabetes: A Growing Challenge in the Healthcare Setting NAME OF STUDENT 2 Type 2 Diabetes: A Growing Challenge in the Healthcare Setting Introduction and background of type 2 diabetes:
More informationINPATIENT DIABETES MANAGEMENT Robert J. Rushakoff, MD Professor of Medicine Director, Inpatient Diabetes University of California, San Francisco
INPATIENT DIABETES MANAGEMENT Robert J. Rushakoff, MD Professor of Medicine Director, Inpatient Diabetes University of California, San Francisco CLINICAL RECOGNITION Background: Appropriate inpatient glycemic
More informationDR. Trinh Thi Kim Hue
TYPE 2 DIABETES IN THE CHILD AND ADOLESCENT DR. Trinh Thi Kim Hue CONTENTS Definition Diagnosis Treatment Comorbidities and Complications Comorbidities and Complications Screening for T2D References DEFINITION
More informationSHORT CLINICAL GUIDELINE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SHORT CLINICAL GUIDELINE SCOPE 1 Guideline title Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes 1.1 Short title Type 2
More informationComparative Review of Oral Hypoglycemic Agents in Adults
SECTION 18.5 Comparative Review of Oral Hypoglycemic Agents in Adults Harinder Chahal For WHO Secretariat Table of Contents Acronyms:... 3 I. Background and Rationale for the review:... 4 II. Medications
More informationOutline: International Diabetes Federation 2013 11/13/2014. Top 10 countries for prevalence (%) of diabetes (20-79 years) - 2013
ZN, 14AY (11/11/2014) 2 Outline: AMERICAN DIABETES ASSOCIATION UPDATES IN STANDARDS OF MEDICAL CARE IN DIABETES - 2014 Dr. Ziad Nasr, BSc Pharm., Pharm.D. Define current criteria for the diagnosis of diabetes
More informationNew and Emerging Diabetes Medications. What do Advanced Practice Nurses Need to Know? Lorraine Nowakowski-Grier,MSN,APRN,BC,CDE
New and Emerging Diabetes Medications What do Advanced Practice Nurses Need to Know? Lorraine Nowakowski-Grier,MSN,APRN,BC,CDE Objectives 1) Describe the clinical indications on select emerging novel diabetes
More informationStatistics of Type 2 Diabetes
Statistics of Type 2 Diabetes Of the 17 million Americans with diabetes, 90 percent to 95 percent have type 2 diabetes. Of these, half are unaware they have the disease. People with type 2 diabetes often
More informationManagement of Diabetes: A Primary Care Perspective. Presentation Outline
Management of Diabetes: A Primary Care Perspective Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Presentation Outline
More informationWhich drugs should be used to treat diabetes in cirrhotic patients?
Which drugs should be used to treat diabetes in cirrhotic patients? Frankfurt am Main 10-12 September 2015 Jörg Bojunga Medizinische Klinik I Johann Wolfgang Goethe-Universität Frankfurt am Main Significance
More informationPEER REVIEW HISTORY ARTICLE DETAILS
PEER REVIEW HISTORY BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (http://bmjopen.bmj.com/site/about/resources/checklist.pdf)
More informationGLUCOPHAGE XR (metformin hydrochloride) Extended-Release Tablets
GLUCOPHAGE (metformin hydrochloride) Tablets GLUCOPHAGE XR (metformin hydrochloride) Extended-Release Tablets DESCRIPTION GLUCOPHAGE (metformin hydrochloride) Tablets and GLUCOPHAGE XR (metformin hydrochloride)
More informationTreatment of diabetes In order to survive, people with type 1 diabetes must have insulin delivered by a pump or injections.
National Diabetes Statistics What is diabetes? Diabetes mellitus is a group of diseases characterized by high levels of blood glucose resulting from defects in insulin production, insulin action, or both.
More informationType 2 diabetes Definition
Type 2 diabetes Definition Type 2 diabetes is a lifelong (chronic) disease in which there are high levels of sugar (glucose) in the blood. Type 2 diabetes is the most common form of diabetes. Causes Diabetes
More informationHypertension and Diabetes Status. 2011 Bangladesh Demographic and Health Survey
Hypertension and Diabetes Status 2011 Bangladesh Demographic and Health Survey Methodology and Sampling Total 18,000 households were selected nationwide (207 in urban and 393 in rural areas) One-third
More informationRenal Disease in Type 2 Diabetes Mellitus
Renal Disease in Type 2 Diabetes Mellitus 6th Collaborative DiGP/HSE/UCC Conference 25 th September 2013 Dr. Eoin O Sullivan Consultant Endocrinologist Bon Secours Hospital Cork Case 69 year old woman
More informationType 2 Diabetes. Aims and Objectives. What did you consider? Case Study One: Miss S. Which to choose?!?! Modes of Action
Aims and Objectives This session will outline the increasing complexities of diabetes care, and the factors that differentiate the combinations of therapy, allowing individualisation of diabetes treatment.
More informationHYPERTENSION ASSOCIATED WITH RENAL DISEASES
RENAL DISEASE v Patients with renal insufficiency should be encouraged to reduce dietary salt and protein intake. v Target blood pressure is less than 135-130/85 mmhg. If patients have urinary protein
More informationNew Treatments for Type 2 Diabetes
New Treatments for Type 2 Diabetes Dr David Hopkins Clinical Director, Division of Ambulatory Care King s College Hospital NHS Foundation Trust Treatments for type 2 diabetes - old & new insulin sulphonylureas
More informationMedical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South
Medical management of CHF: A New Class of Medication Al Timothy, M.D. Cardiovascular Institute of the South Disclosures Speakers Bureau for Amgen Background Chronic systolic congestive heart failure remains
More informationHigh Blood Cholesterol
National Cholesterol Education Program ATP III Guidelines At-A-Glance Quick Desk Reference 1 Step 1 2 Step 2 3 Step 3 Determine lipoprotein levels obtain complete lipoprotein profile after 9- to 12-hour
More informationThe basal plus strategy. Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE
The basal plus strategy Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE ADA/EASD guidelines recommend use of basal insulin as early as the second step
More informationQuick Reference Guide
2013 Clinical Practice Guidelines Quick Reference Guide (Updated March 2016) 416569-16 guidelines.diabetes.ca diabetes.ca 1-800-BANTING (226-8464) Copyright 2016 Canadian Diabetes Association SCREENING
More informationNewer Anticoagulants and Newer Diabetic Drug Classes. Nicole N. Nguyen, PharmD Senior Clinical Pharmacist Health Care Services August 21, 2013
Newer Anticoagulants and Newer Diabetic Drug Classes Nicole N. Nguyen, PharmD Senior Clinical Pharmacist Health Care Services August 21, 2013 Apixaban Newer Anticoagulants Dabigatran etexilate Rivaroxaban
More informationStarlix DESCRIPTION CLINICAL PHARMACOLOGY. (nateglinide) tablets Rx only Prescribing Information. Mechanism of Action
Starlix (nateglinide) tablets Rx only Prescribing Information DESCRIPTION Starlix (nateglinide) is an oral antidiabetic agent used in the management of Type 2 diabetes mellitus [also known as non-insulin
More informationRobert Okwemba, BSPHS, Pharm.D. 2015 Philadelphia College of Pharmacy
Robert Okwemba, BSPHS, Pharm.D. 2015 Philadelphia College of Pharmacy Judith Long, MD,RWJCS Perelman School of Medicine Philadelphia Veteran Affairs Medical Center Background Objective Overview Methods
More informationDrug Class Review. Newer Diabetes Medications and Combinations
Drug Class Review Newer Diabetes Medications and Combinations Final Streamlined Update 1 Report June 2014 The purpose of Drug Effectiveness Review Project reports is to make available information regarding
More informationPowerPoint Lecture Outlines prepared by Dr. Lana Zinger, QCC CUNY. 12a. FOCUS ON Your Risk for Diabetes. Copyright 2011 Pearson Education, Inc.
PowerPoint Lecture Outlines prepared by Dr. Lana Zinger, QCC CUNY 12a FOCUS ON Your Risk for Diabetes Your Risk for Diabetes! Since 1980,Diabetes has increased by 50 %. Diabetes has increased by 70 percent
More informationBelow, this letter outlines [patient name] s medical history, prognosis, and treatment rationale.
[Date] [Name of Contact] [Title] [Name of Health Insurance Company] [Address] [City, State, Zip Code] Insured: [Patient Name] Policy Number: [Number] Group Number: [Number] Diagnosis: [Diagnosis and ICD-9-CM
More informationINSULIN AND INCRETIN THERAPIES: WHAT COMBINATIONS ARE RIGHT FOR YOUR PATIENT?
INSULIN AND INCRETIN THERAPIES: WHAT COMBINATIONS ARE RIGHT FOR YOUR PATIENT? MARTHA M. BRINSKO, MSN, ANP-BC CHARLOTTE COMMUNITY HEALTH CLINIC CHARLOTTE, NC Diagnosed and undiagnosed diabetes in the United
More informationStatins and Risk for Diabetes Mellitus. Background
Statins and Risk for Diabetes Mellitus Kevin C. Maki, PhD, FNLA Midwest Center for Metabolic & Cardiovascular Research and DePaul University, Chicago, IL 1 Background In 2012 the US Food and Drug Administration
More informationINITIATING ORAL AUBAGIO (teriflunomide) THERAPY
FOR YOUR PATIENTS WITH RELAPSING FORMS OF MS INITIATING ORAL AUBAGIO (teriflunomide) THERAPY WARNING: HEPATOTOXICITY AND RISK OF TERATOGENICITY Severe liver injury including fatal liver failure has been
More informationInsulin is a hormone produced by the pancreas to control blood sugar. Diabetes can be caused by too little insulin, resistance to insulin, or both.
Diabetes Definition Diabetes is a chronic (lifelong) disease marked by high levels of sugar in the blood. Causes Insulin is a hormone produced by the pancreas to control blood sugar. Diabetes can be caused
More informationSponsor Novartis. Generic Drug Name Secukinumab. Therapeutic Area of Trial Psoriasis. Approved Indication investigational
Clinical Trial Results Database Page 2 Sponsor Novartis Generic Drug Name Secukinumab Therapeutic Area of Trial Psoriasis Approved Indication investigational Clinical Trial Results Database Page 3 Study
More information